Cancer - Encouraging results for second-generation antiangiogenesis drugs

The strategy of denying growing tumors a blood supply continues to show clinical promise as new and improved drugs move through the pipeline. Early last year, the US FDA approved the first cancer drug, an antibody called Avastin, thatis specifically designed to prevent this tumor angiogenesis, as the new bloodvessel growth is called. One advanced clinical trial showed that a new antiangiogenesis drug called, sorafenib significantly slows metastatic kidney cancerand another drug known as Sutent proved its mettle in treating a digestive system cancer called gastrointestinal stromal tumor.